<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597790</url>
  </required_header>
  <id_info>
    <org_study_id>12-001792 (CTSI-PLACE)</org_study_id>
    <secondary_id>N/A (Parent P30AI028697)</secondary_id>
    <secondary_id>N/A (Parent UL1TR000124)</secondary_id>
    <secondary_id>52767</secondary_id>
    <nct_id>NCT02597790</nct_id>
  </id_info>
  <brief_title>A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects</brief_title>
  <acronym>CTSI-PLACE</acronym>
  <official_title>Clinical and Translational Science Institute Prospective Longitudinal Assessment of Coinfected Subjects With HIV/Hepatitis C for Endothelial Function Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CTSI-PLACE Study is a study for men and women with HIV/hepatitis C co-infection or HIV&#xD;
      only. The study looks at the impact of having hepatitis C virus in addition to HIV on risk&#xD;
      for cardiovascular disease. Participants will undergo non-invasive assessment of&#xD;
      cardiovascular disease risk through measurements of endothelial function and blood biomarkers&#xD;
      at baseline and 1 year (or 4 weeks and 24 weeks after end of HCV treatment for those that&#xD;
      undergo HCV treatment during study follow-up).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reactive hyperemia index (RHI) by peripheral arterial tonometry (PAT)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Soluble biomarkers (fasting lipid panel, hsCRP, IL-6, D-dimer, sICAM-1, sE-selectin, Lp-PLA2, sCD14, sCD163)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive hyperemia index (RHI)</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble biomarkers (fasting lipid panel, hsCRP, IL-6, D-dimer, sICAM-1, sE-selectin, Lp-PLA2, sCD14, sCD163)</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance by HOMA-IR</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance by HOMA-IR</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Framingham risk score (FRS)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Framingham risk score (FRS)</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RHI</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of each soluble biomarker (components of fasting lipid panel, hsCRP, IL-6, D-dimer, sICAM-1, sE-selectin, Lp-PLA2, sCD14, sCD163)</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FRS</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">87</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group A (HIV/HCV coinfected)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (HIV monoinfected)</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV/HCV coinfected and HIV monoinfected adults with well-controlled HIV&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Men and women â‰¥ 18 years&#xD;
&#xD;
          2. Hepatitis C negative or chronic hepatitis C infection&#xD;
&#xD;
          3. Chronic HIV infection&#xD;
&#xD;
          4. CD4+ T-cell count &gt; 200 cells/mm3&#xD;
&#xD;
          5. Plasma HIV-1 RNA &lt; 50 copies/mL&#xD;
&#xD;
          6. On continuous and stable ART for at least 12 weeks&#xD;
&#xD;
          7. Ability and willingness to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Known cardiovascular disease&#xD;
&#xD;
          2. Diabetes requiring insulin therapy or hemoglobin A1c &gt; 8%&#xD;
&#xD;
          3. Inability to conform to requirements for PAT testing&#xD;
&#xD;
          4. Decompensated liver disease&#xD;
&#xD;
          5. Other known causes of significant liver disease&#xD;
&#xD;
          6. Serious illness including acute liver-related disease and malignancy requiring&#xD;
             systemic treatment or hospitalization within 12 weeks prior to study entry&#xD;
&#xD;
          7. Presence of active or acute AIDS-defining opportunistic infections (OIs) within 12&#xD;
             weeks prior to study entry&#xD;
&#xD;
          8. History of major organ transplantation with an existing functional graft and on&#xD;
             immunosuppressive therapy&#xD;
&#xD;
          9. History of known vascular or autoimmune disease&#xD;
&#xD;
         10. Pregnancy&#xD;
&#xD;
         11. HCV treatment (any approved or investigational agents) within 24 weeks prior to study&#xD;
             entry&#xD;
&#xD;
         12. Use of immune-based therapies or systemic corticosteroids within 12 weeks prior to&#xD;
             study entry&#xD;
&#xD;
         13. Advanced renal insufficiency as defined by glomerular filtration rate (GFR) &lt; 30&#xD;
             mL/min/1.73 m2 or treatment by dialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kara W. Chew, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>April 5, 2020</last_update_submitted>
  <last_update_submitted_qc>April 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Kara Chew</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>HIV</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>metabolic disease</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 30, 2021</submitted>
    <returned>February 18, 2021</returned>
    <submitted>September 28, 2021</submitted>
    <returned>October 26, 2021</returned>
    <submitted>October 31, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

